Protagonist Therapeutics price target raised to $180 by Barclays
Barclays raised its price target on Protagonist Therapeutics to $180.00 per share from $153.00, according to Benzinga (via TradingView News).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.